Search

Your search keyword '"S, Tam"' showing total 28 results
Start Over Author "S, Tam" Journal hematological oncology
28 results on '"S, Tam"'

1. PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417

Author

Chan Yoon Y. Cheah, Stephen Opat, Constantine S. Tam, Y. Gao, Emma Verner, D. Simpson, J. Huang, and J. Hilger

Subjects
Cancer Research, medicine.anatomical_structure, Oncology, business.industry, Relapsed refractory, Cancer research, Medicine, Hematology, General Medicine, business, B-cell lymphoma, medicine.disease, B cell
Published
2021
Full Text
View/download PDF

2. FIRST‐LINE IBRUTINIB + VENETOCLAX TREATMENT FOR MANTLE CELL LYMPHOMA IN OLDER PATIENTS OR THOSE WITH TP53 MUTATION: A NEW OPEN‐LABEL ARM OF THE PHASE 3 PCYC‐1143 SYMPATICO STUDY

Author

Wojciech Jurczak, J. Lin, Mengjun Wang, J. K. Neuenburg, Constantine S. Tam, and K. Eckert

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, First line, Hematology, General Medicine, Tp53 mutation, medicine.disease, chemistry.chemical_compound, Older patients, chemistry, Internal medicine, Ibrutinib, medicine, Mantle cell lymphoma, Open label, business
Published
2021
Full Text
View/download PDF

3. TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES

Author

Stanley Cheung, H.P. Miskin, Tomasz Wróbel, Owen A. O'Connor, Krzysztof Giannopoulos, Wojciech Jurczak, C. K Yannakou, C.Y. Cheah, A. D Ricart, Nicholas Wickham, J. P. Tang, M. Lasica, Katharine L Lewis, Jan Walewski, Constantine S. Tam, E. Normant, and M. Długosz-Danecka

Subjects
Cancer Research, medicine.medical_specialty, biology, business.industry, Atrial fibrillation, Hematology, General Medicine, medicine.disease, Gastroenterology, Discontinuation, Oncology, Refractory, Chemoimmunotherapy, Internal medicine, Cohort, Toxicity, medicine, biology.protein, Bruton's tyrosine kinase, Adverse effect, business
Abstract

Introduction: TG-1701 is a selective, covalent BTK inhibitor administered once daily (QD). Both the “U2” combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ϵ inhibitor umbralisib) and BTK inhibition are highly active in treatment-naive (TN) and relapsed/ refractory (R/R) CLL, each having previously demonstrated superiority over standard chemoimmunotherapy. Herein we report the results of the dose escalation of TG-1701 monotherapy and TG-1701+U2. Methods: Patients (pts) with R/R CLL, MCL and Waldenstrom's (WM) were enrolled in an ongoing Ph 1 study initially evaluating dose escalation (DE) of oral TG-1701 QD continuously administered in 28-day cycles (100, 200, 300, and 400 mg). After characterizing the safety profile of TG-1701 monotherapy, we implemented a parallel DE arm of TG-1701+U2. Select dose levels of TG-1701 monotherapy were expanded. All pts were treated until disease progression, unacceptable toxicity, or investigator/patient decision to withdraw. Results: As of 03 February 2021, 123 pts were treated with TG-1701 as follows: 25 in the monotherapy DE arm, 61 in the 200 mg disease-specific cohorts (20 CLL [5 TN], 21 MCL [4 TN], 20 WM [8 TN]), 20 in the 300 mg CLL cohort (4 TN), and 17 in the 1701+U2 DE arm. The median # of prior therapies was 1 (range, 1-10). All pts were BTKi-naive. All 123 pts were evaluable for safety. TG-1701 was well tolerated and the maximum tolerated dose (MTD) for monotherapy was not reached at 400 mg (demonstrating near 100% saturation of the BTK at all dose levels studied). Treatment emergent adverse events (TEAE) of clinical interest included atrial fibrillation (AF 4.0% of pts, G ≥3 in 1 case), G ≥3 hypertension (2.4%), and bleeding events (18.7%, all G1-2). No cases of ventricular tachyarrhythmia were reported. TEAEs leading to TG-1701 dose reduction occurred in 6.5% of pts. TEAEs leading to treatment discontinuation occurred in 1.6% of pts (AF, COVID-19). At the data cut-off, 119 pts were evaluable for response, including 40 in DE (Table). The median duration of response has not been reached among responders overall. The median follow-up (mFU range) was 15.9 mos (1.3-28.6+) in DE and 8.5 mos (1.4-15.6+) in disease-specific cohorts. Best change from baseline in tumor burden in pts in the 1701+U2 combination arm is presented in the figure below. Conclusions: TG-1701 exhibits an encouraging safety and efficacy profile. The combination of 1701+U2 has been well tolerated and dose escalation continues. The combination shows enhanced depth of response over TG-1701 monotherapy.

Published
2021
Full Text
View/download PDF

4. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Author

Edith Szafer-Glusman, John N. Allan, C. Zhou, Livio Trentin, Bryone J. Kuss, Rajat Bannerji, Paul M. Barr, Carol Moreno, K. Russell, Sharon Jackson, J. Ninomoto, Alessandra Tedeschi, R Jacobs, James P. Dean, Paolo Ghia, Stephen Opat, Thomas J. Kipps, Constantine S. Tam, Tanya Siddiqi, and William G. Wierda

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Venetoclax, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Lymphocytic lymphoma, First line treatment, chemistry.chemical_compound, Fixed duration, chemistry, Internal medicine, Ibrutinib, Medicine, business
Published
2021
Full Text
View/download PDF

5. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)

Author

D. Simpson, Constantine S. Tam, Mengjun Wang, R. Wei, R. Elstrom, Gavin Cull, Stephen Opat, Judith Trotman, J. Huang, S. Atwal, W.S. Kim, Javier Munoz, and Tycel Phillips

Subjects
Cancer Research, Oncology, biology, business.industry, Cancer research, biology.protein, Bruton's tyrosine kinase, Medicine, Mantle cell lymphoma, Hematology, General Medicine, business, medicine.disease
Published
2019
Full Text
View/download PDF

6. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Author

Ian W. Flinn, Ulrich Jäger, Hagop Youssoufian, David T. Weaver, Gabriel Etienne, Stephan Stilgenbauer, Árpád Illés, Florence Cymbalista, Matthew S. Davids, Constantine S. Tam, Marco Montillo, Bryone J. Kuss, Francesc Bosch, Julio Delgado, Fritz Offner, Nicole Lamanna, Stephanie Lustgarten, and Paolo Ghia

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Duvelisib, chemistry.chemical_compound, chemistry, Internal medicine, Relapsed refractory, medicine, In patient, business
Published
2019
Full Text
View/download PDF

7. RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Author

Constantine S. Tam, Rod Ramchandren, Graham P. Collins, Mengjun Wang, Robert T. Chen, G. Chong, V. Fedorov, Kevin J. Freise, J. Neuenburg, Y. Lee, J. Sukbuntherng, E. Dobkowska, Mark Bishton, Wojciech Jurczak, Frederic Peyrade, K. Wu, Lionel Karlin, and P. Eliadis

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Hematology, General Medicine, Run-in period, medicine.disease, chemistry.chemical_compound, chemistry, Ibrutinib, Internal medicine, Relapsed refractory, medicine, In patient, Mantle cell lymphoma, business
Published
2019
Full Text
View/download PDF

8. PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Author

Beatrice Mahe, Chaim Shustik, Christian Buske, Maria Lia Palomba, David MacDonald, E Kastritis, Ramón García-Sanz, Marzia Varettoni, Judith Trotman, Veronique Leblond, Alessandra Tedeschi, E.G. Poulsen, Jianyong Li, Leonard T. Heffner, Jeffrey Matous, Charles Herbaux, Steven P. Treon, B. Hauns, Constantine S. Tam, and Meletios-Athanassios Dimopoulos

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Waldenstrom macroglobulinemia, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Ibrutinib, medicine, Rituximab, business, medicine.drug
Published
2019
Full Text
View/download PDF

9. CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMAS

Author

Andreas Kiesbye Øvlisen, Mark Hertzberg, H. Chuah, K. Bavishi, John F. Seymour, C.Y. Cheah, Constantine S. Tam, Ian Bilmon, Mark R. Dowling, David Ritchie, Henry Miles Prince, T.C. El-Galaly, Max Wolf, Robin Filshie, Nada Hamad, Katharine L Lewis, S. P'Ng, Andrew Grigg, and P. Choi

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Hematology, General Medicine, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, Internal medicine, Relapsed refractory, medicine, In patient, business, B cell
Published
2019
Full Text
View/download PDF

10. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL

Author

Koji Izutsu, Harald Holte, Koji Kato, Alessandra Forcina, Michael R. Bishop, Ulrich Jaeger, Jason R. Westin, Joseph P. McGuirk, Richard T. Maziarz, Edmund K. Waller, Peter Borchmann, Veronika Bachanova, Stephen J. Schuster, K. Van Besien, Phoebe Joy Ho, Isabelle Fleury, Stephan Mielke, Stephen Ronan Foley, Paolo Corradini, Marie-Jose Kersten, Constantine S. Tam, Ranjan Tiwari, Takanori Teshima, Charalambos Andreadis, Samantha Jaglowski, Lida Bubuteishvili Pacaud, Gilles Salles, and Nina D. Wagner-Johnston

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Gastroenterology, Intravenous Immunoglobulin Therapy, Oncology, Internal medicine, Relapsed refractory, Medicine, In patient, business, Diffuse large B-cell lymphoma
Published
2019
Full Text
View/download PDF

11. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY

Author

Julio C. Chavez, D. Simpson, Oren Pasvolsky, Samar Issa, Kenneth H. Shain, Lia Palomba, Marzia Varettoni, Lakshmi Nayak, Jorge J. Castillo, Alessandra Tedeschi, Toby A. Eyre, Jonas Paludo, Dipti Talaulikar, Steven P. Treon, Constantine S. Tam, S. M. Ansell, Gilad Itchaki, and Christian Buske

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, chemistry.chemical_compound, Multicenter study, chemistry, Internal medicine, Ibrutinib, Medicine, business, Bing–Neel syndrome
Published
2019
Full Text
View/download PDF

12. AN IMPROVED BENEFIT-RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

Author

Ian W. Flinn, S. Stilgenbauer, Stephanie Lustgarten, David T. Weaver, Florence Cymbalista, Hagop Youssoufian, Bryone J. Kuss, Paolo Ghia, Matthew S. Davids, Marco Montillo, Ulrich Jäger, Constantine S. Tam, Peter Hillmen, and Julio Delgado

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Duvelisib, Risk profile, Lymphocytic lymphoma, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business
Published
2019
Full Text
View/download PDF

13. ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Author

R. Eek, W. Reed, J. Huang, Michael F. Leahy, L. Wang, A. Nicol, Ian W. Flinn, Sushrut Patil, Henry Miles Prince, Hang Quach, R. Prathikanti, Xavier Badoux, Constantine S. Tam, Nicholas Wickham, and Hannah Rose

Subjects
Cancer Research, business.industry, Chronic lymphocytic leukemia, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Lymphocytic lymphoma, chemistry.chemical_compound, Oncology, chemistry, Obinutuzumab, Relapsed refractory, Cancer research, Medicine, In patient, business
Published
2019
Full Text
View/download PDF

14. AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

Author

Neil Came, Sasanka M. Handunnetti, Surender Juneja, David Westerman, John F. Seymour, Victor S Lin, Thomas E Lew, Andrew W. Roberts, Dennis A. Carney, Max Wolf, Constantine S. Tam, and Mary-Ann Anderson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Venetoclax, Hematology, General Medicine, Therapeutic goal, chemistry.chemical_compound, chemistry, Internal medicine, Relapsed refractory, Medicine, business
Published
2019
Full Text
View/download PDF

15. LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP

Author

Ulrich Jaeger, D.F. James, Constantine S. Tam, Richard R. Furman, Susan O'Brien, John C. Byrd, Jeffrey A. Jones, Peter Hillmen, Jennifer R. Brown, Paul M. Barr, Marco Montillo, N.M. Reddy, R. Vezan, S. Dai, Thomas J. Kipps, Stephen P. Mulligan, Carol Moreno, John M. Pagel, Jaqueline C. Barrientos, S. E. Coutre, Jan A. Burger, and Patrick Thornton

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Ibrutinib, medicine, In patient, business, Previously treated
Published
2017
Full Text
View/download PDF

16. A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

Author

Constantine S. Tam, S. Atwal, Alessandra Tedeschi, Veronique Leblond, W. Novotny, Christian Buske, A. Cohen, J. Huang, and Roger G. Owen

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Head to head, business.industry, Waldenstrom macroglobulinemia, Phases of clinical research, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Ibrutinib, medicine, In patient, business
Published
2017
Full Text
View/download PDF

17. COMPARISON OF INNATE IMMUNITY CHANGES FOLLOWING IBRUTINIB AND VENETOCLAX TREATMENT OF RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA

Author

Constantine S. Tam, Rachel Koldej, Kylie D. Mason, Joanne E. Davis, David Ritchie, and Chia Sharpe

Subjects
Cancer Research, Lymphocytic leukaemia, Innate immune system, business.industry, Venetoclax, Hematology, General Medicine, chemistry.chemical_compound, Oncology, chemistry, Ibrutinib, Immunology, Medicine, business
Published
2017
Full Text
View/download PDF

18. OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX

Author

John F. Seymour, Constantine S. Tam, Thomas E Lew, Andrew W. Roberts, and Mary-Ann Anderson

Subjects
Cancer Research, biology, business.industry, Venetoclax, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Lymphocytic lymphoma, chemistry.chemical_compound, Oncology, chemistry, Relapsed refractory, medicine, Cancer research, biology.protein, Bruton's tyrosine kinase, business
Published
2017
Full Text
View/download PDF

19. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY

Author

Bradley Augustson, Andrew W. Roberts, L. Xue, Stephen Opat, J. Huang, Won Seog Kim, Mary Ann Anderson, Sumita Ratnasingam, Matthew Ku, Paula Marlton, John F. Seymour, Gavin Cull, Constantine S. Tam, D. Simpson, E. Hedrick, J. Hilger, David Gottlieb, Judith Trotman, L. Wang, and David Ritchie

Subjects
0301 basic medicine, Cancer Research, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Lymphocytic lymphoma, 03 medical and health sciences, BTK Inhibitor BGB-3111, 030104 developmental biology, 0302 clinical medicine, Overall response rate, Oncology, 030220 oncology & carcinogenesis, medicine, Cancer research, In patient, business
Published
2017
Full Text
View/download PDF

20. PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL)

Author

L.C. Tsao, Constantine S. Tam, Umberto Vitolo, S. Le Gouill, Mengjun Wang, Simon Rule, N. Cavazos, and D.M. Beaupre

Subjects
Cancer Research, business.industry, Venetoclax, Phases of clinical research, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Oncology, chemistry, 030220 oncology & carcinogenesis, Ibrutinib, Relapsed refractory, Cancer research, Medicine, In patient, Mantle cell lymphoma, 030212 general & internal medicine, business
Published
2017
Full Text
View/download PDF

21. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

Author

David Gottlieb, Paula Marlton, Mary Ann Anderson, D. Simpson, L. Wang, David Ritchie, Andrew W. Roberts, Constantine S. Tam, Sumita Ratnasingam, John F. Seymour, Gavin Cull, E. Hedrick, L. Xue, Peter Wood, Stephen Opat, J. Hilger, Emma Verner, J. Huang, and Judith Trotman

Subjects
0301 basic medicine, Very Good Partial Response, Cancer Research, biology, business.industry, Waldenstrom macroglobulinemia, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, BTK Inhibitor BGB-3111, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Medicine, Bruton's tyrosine kinase, In patient, business
Published
2017
Full Text
View/download PDF

22. EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author

Paul M. Barr, Ian W. Flinn, S. E. Coutre, D.F. James, Constantine S. Tam, J. Ninomoto, Thomas J. Kipps, Paolo Ghia, William G. Wierda, Jan A. Burger, Jeffrey P. Sharman, Don A. Stevens, Susan O'Brien, C. Zhou, Richard R. Furman, and John C. Byrd

Subjects
Cancer Research, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, Tumor Debulking, Tumor lysis syndrome, chemistry.chemical_compound, Oncology, chemistry, Ibrutinib, Immunology, Cancer research, Medicine, In patient, Single agent, business
Published
2017
Full Text
View/download PDF

23. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia

Author

Constantine S. Tam and Issa F. Khouri

Subjects
Male, Oncology, Cancer Research, Transplantation Conditioning, Antibodies, Neoplasm, medicine.medical_treatment, Myeloablative Agonist, Hematopoietic stem cell transplantation, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Multicenter Studies as Topic, Alemtuzumab, Clinical Trials as Topic, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Hematology, General Medicine, Middle Aged, Combined Modality Therapy, Leukemia, Treatment Outcome, surgical procedures, operative, Female, Rituximab, Immunotherapy, Stem cell, therapeutics, Whole-Body Irradiation, medicine.drug, Adult, medicine.medical_specialty, Graft vs Leukemia Effect, Antibodies, Monoclonal, Humanized, Transplantation, Autologous, Disease-Free Survival, Internal medicine, medicine, Humans, Transplantation, Homologous, Aged, Salvage Therapy, business.industry, Myeloablative Agonists, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Transplantation, Immunology, business, human activities
Abstract

The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL.

Published
2009
Full Text
View/download PDF

24. GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS

Author

Rakesh Awasthi, Peter Borchmann, Lida Bubuteishvili Pacaud, Phoebe Joy Ho, Charalambos Andreadis, Stephen Ronan Foley, Edmund K. Waller, Gilles Salles, Samantha Jaglowski, Stephan Mielke, Feng Tai, Veronika Bachanova, Joseph P. McGuirk, Özlem Anak, Richard T. Maziarz, Stephen J. Schuster, Ulrich Jäger, Isabelle Fleury, Jason R. Westin, Constantine S. Tam, Harald Holte, and Michael R. Bishop

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Adult patients, biology, business.industry, medicine.medical_treatment, Hematology, General Medicine, medicine.disease, Interim analysis, CD19, Targeted therapy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Refractory, 030220 oncology & carcinogenesis, Internal medicine, medicine, biology.protein, business, Diffuse large B-cell lymphoma
Published
2017
Full Text
View/download PDF

25. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author

A. Nicol, W. Novotny, J. Huang, E. Hedrick, Michael F. Leahy, Sushrut Patil, L. Wang, Hang Quach, Henry Miles Prince, Hannah Rose, Nicholas Wickham, R. Eek, X. Zhang, Xavier Badoux, Constantine S. Tam, and Ian W. Flinn

Subjects
0301 basic medicine, CD20, Cancer Research, biology, business.industry, Chronic lymphocytic leukemia, Follicular lymphoma, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, BTK Inhibitor BGB-3111, 030104 developmental biology, 0302 clinical medicine, Oncology, chemistry, Obinutuzumab, 030220 oncology & carcinogenesis, medicine, Cancer research, biology.protein, In patient, business
Published
2017
Full Text
View/download PDF

26. AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL

Author

K. Eckert, Ian W. Flinn, K. Russell, D.F. James, Constantine S. Tam, Paolo Ghia, William G. Wierda, C. Zhou, Tanya Siddiqi, Don A. Stevens, and J. Ninomoto

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Venetoclax, Phases of clinical research, Hematology, General Medicine, Therapy naive, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Ibrutinib, Internal medicine, Medicine, In patient, business, 030215 immunology
Published
2017
Full Text
View/download PDF

27. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels

Author

Hsy Liu, W. K. Wong, Hak-Kim Chan, MF Law, Wwc Chu, Wwm Lam, S Tam, Rhs Liang, and Wing-Yan Au

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Hemosiderosis, Heart Diseases, Ferritin levels, Pilot Projects, Gastroenterology, Asian People, hemic and lymphatic diseases, Internal medicine, medicine, Endocrine system, Humans, Aplastic anemia, Subclinical infection, Aged, Aged, 80 and over, Ejection fraction, business.industry, Incidence (epidemiology), Anemia, Aplastic, Pancreatic Diseases, Transfusion Reaction, Hematology, General Medicine, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Oncology, Heart failure, Myelodysplastic Syndromes, Ferritins, Female, business, Cardiomyopathies
Abstract

We performed MRI and endocrine assessment in 27 adult Chinese patients with severe aplastic anemia (SAA) and myelodysplasia (MDS). Despite high ferritin levels, cardiac hemosiderosis and heart failure was not common, and were not concordant in most cases. However, significant correlation was found between cardiac T2/T2* MRI assessment, ejection fraction and ferritin levels. Furthermore, there was a high incidence subclinical pancreatic abnormality that was related to liver MRI T2* readings. Hence, chelating agents may still have a role to improve organ function. Prospective data with serial functional and imaging monitoring is needed. Copyright © 2008 John Wiley & Sons, Ltd.

Published
2008

28. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels.

Author

Au W, Lam W, Chu W, Tam S, Wong W, Chan H, Law M, Liu H, and Liang R

Subjects
Adult, Aged, Aged, 80 and over, Asian People, Cardiomyopathies complications, Cardiomyopathies diagnosis, Female, Heart Diseases complications, Hemosiderosis complications, Hemosiderosis metabolism, Humans, Male, Middle Aged, Pancreatic Diseases complications, Pancreatic Diseases diagnosis, Pilot Projects, Transfusion Reaction, Anemia, Aplastic complications, Ferritins analysis, Hemosiderosis diagnosis, Magnetic Resonance Imaging, Myelodysplastic Syndromes complications
Abstract

We performed MRI and endocrine assessment in 27 adult Chinese patients with severe aplastic anemia (SAA) and myelodysplasia (MDS). Despite high ferritin levels, cardiac hemosiderosis and heart failure was not common, and were not concordant in most cases. However, significant correlation was found between cardiac T2/T2* MRI assessment, ejection fraction and ferritin levels. Furthermore, there was a high incidence subclinical pancreatic abnormality that was related to liver MRI T2* readings. Hence, chelating agents may still have a role to improve organ function. Prospective data with serial functional and imaging monitoring is needed., (Copyright (c) 2008 John Wiley & Sons, Ltd.)

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results